Status:
RECRUITING
A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors
Lead Sponsor:
BeOne Medicines
Conditions:
Solid Tumor
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a first-in-human (FIH) study that will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-R046 as a single agent and in combi...
Detailed Description
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this...
Eligibility Criteria
Inclusion
- Participants able to provide a signed and dated written informed consent prior to any study-specific procedures, sampling, or data collection
- Participants with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have previously received standard systemic therapy or for whom standard treatment is not available, not tolerated, or determined not appropriate based on the investigator's judgement
- ≥ 1 measurable lesion per RECIST v1.1
- Able to provide an archived tumor tissue sample
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1
- Adequate organ function
- Life expectancy \>12 weeks as determined by the investigator
Exclusion
- Active leptomeningeal disease or uncontrolled, untreated brain metastasis
- Active autoimmune diseases or history of autoimmune diseases that may relapse
- Any malignancy ≤ 3 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast)
- Any condition that required systemic treatment with either corticosteroids (\> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before the first dose of study drug(s)
- History of interstitial lung disease, noninfectious pneumonitis (including immune mediated), or uncontrolled lung diseases including pulmonary fibrosis, or acute lung diseases.
- Experienced ≥ Grade 3 imAE(s) on prior immuno-oncology agent (anti-PD-1, anti CTLA4, or other experimental drugs)
- Uncontrolled diabetes \> Grade 1 laboratory test abnormalities in potassium, sodium, or corrected calcium despite standard medical management, or ≥ Grade 3 hypoalbuminemia ≤ 14 days before the first dose of study drug(s).
- Infection (including tuberculosis infection, or other) requiring systemic (oral or intravenous) antibacterial, antifungal, or antiviral therapy ≤ 14 days before the first dose of study drug(s)
- Immunodeficiency as assessed by the investigator to be not suitable for treatment with immune modulating anticancer agents
- NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
July 16 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT06487858
Start Date
July 16 2024
End Date
December 1 2027
Last Update
January 8 2026
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Fujian Cancer Hospital
Fuzhou, Fujian, China, 350014
2
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China, 530021
3
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430022
4
The First Hospital of China Medical University
Shenyang, Liaoning, China, 110001